Contrast-enhanced MRI in Children 2 Months to <2 Years

Open-label, Multi-center, Two-stage, Age Stratified, Pharmacokinetic, Safety, and Efficacy Study in Children 2 Months to < 2 Years of Age Undergoing Magnevist Injection Enhanced MRI

The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age

Safety issues are addressed in the AE section

Inclusion Criteria:

• Age: 2 months to < 2 years (23 months)
• Participants (male/female) who are scheduled to undergo gadolinium-enhanced MRI
• Able to comply with the study procedures

Exclusion Criteria:

• Clinical unstable participants (eg, intensive care unit)
• Renal Insufficiency
• Participants undergoing chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Magnevist.